Anda di halaman 1dari 7

Analysis of the US Neurovascular Intervention Market

Large Opportunities in Expanding Treatment Options and New Technologies

NC3F-54

July 2013

Executive Summary

Executive Summary

Total revenue generated by sales of neurovascular intervention market in the US in 2012 was approximately $273.0 million.

Revenue in the US neurovascular intervention market is projected to grow at a compound annual growth rate (CAGR) of 7.6 percent from 2012 to 2017, reaching $392.8 million in 2017.

Currently, the largest market segment is the neurovascular coils market, while the smallest is the liquid embolics market.

The segment with the highest CAGR is the stent retriever market, since the first stent retriever in the US was launched in early 2012. More stent retrievers are expected to enter the US market in the coming years.

The high growth rate in the stent retriever market is likely to offset the trends in the relatively stable coils and liquid embolics markets, leading to the growth of the overall neurovascular intervention market.

Source: Frost & Sullivan

Executive Summary (continued)

There is great uncertainty surrounding the future of the neurovascular coils segment because of emerging flow-diversion devices’ potential to become both a complement and a substitute to coils for aneurysm treatment.

The US liquid embolics segment is essentially a monopoly as the Food and Drug Administration (FDA) has placed the only product available under very restricted use for fewer than 4,000 patients in the US.

Ischemic stroke patients had been previously underserved with only one treatment option; thus, companies are now eager to develop and introduce stent retrievers to the US market with a large patient base and high growth potential.

The overall US neurovascular intervention market is very concentrated with only a few large manufacturers because of high barriers to entry, most notably the 510(k) clearance required from the US FDA.

Source: Frost & Sullivan

Executive SummaryMarket Engineering Measurements

Total Neurovascular Intervention Market: US, 2012

Market Overview Market Market Stage Market Revenue Average Price* Units/Volume Market Size for Last Year of
Market Overview
Market
Market Stage
Market Revenue
Average Price*
Units/Volume
Market Size for
Last Year of
Study Period
Growth
$273.0 M
174,257
$2,890.9
$392.8
(2012)
(2012)
(2017)
Base Year Market Growth Rate Compound Annual Growth Rate Degree of Customer Price Sensitivity Technical Change
Base Year
Market Growth
Rate
Compound
Annual Growth
Rate
Degree of
Customer Price
Sensitivity
Technical
Change
7.6%
24.6%
7
6
(CAGR, 2012–2017)
(scale:1 [Low] to 10 [High])
(scale:1 [Low] to 10 [High])
Decreasing Stable Increasing
Decreasing
Stable
Increasing

For a tabular version click here.

*Weighted Average Selling Price Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan

Executive SummaryMarket Engineering Measurements (continued)

Competitor Overview Industry Advancement Average Number of Competitors* Number of Companies that Entered Product Development Time
Competitor Overview
Industry Advancement
Average
Number of
Competitors*
Number of
Companies that
Entered
Product
Development
Time
5
About 10
0
Years
(active market competitors in
base year)
(2012)
Decreasing Stable Increasing NC3F-54
Decreasing
Stable
Increasing
NC3F-54

*About 10 with revenue greater than $1.0 million USD Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan

8

Executive Summary—CEO’s Perspective

Rising ischemic stroke prevalence 1 represents a largely unpenetrated market for solution providers.
Rising ischemic stroke prevalence
1
represents a largely unpenetrated
market for solution providers.
Shorter recovery time for products like 2 liquid embolics is an attractive option for hospitals looking
Shorter recovery time for products like
2
liquid embolics is an attractive option
for hospitals looking to cut costs.
Growth through mergers and 3 acquisitions is a growing trend to acquire niche technologies.
Growth through mergers and
3
acquisitions is a growing trend to
acquire niche technologies.
Published data on new clinical trials will 4 motivate physicians and surgeons to use new methods
Published data on new clinical trials will
4
motivate physicians and surgeons to
use new methods of treatment.
Flow diversion devices are a looming 5 threat to the coils market, due to their benefits
Flow diversion devices are a looming
5
threat to the coils market, due to their
benefits in wide-neck aneurysms.
Executive Summary —CEO’s Perspective Rising ischemic stroke prevalence 1 represents a largely unpenetrated market for solution

Source: Frost & Sullivan

NC3F-54

9